Valproic acid in childhood epilepsy: anticonvulsive efficacy in relation to its plasma levels

International Journal of Clinical Pharmacology, Therapy, and Toxicology
|October 1, 1980
PubMed

Insights

Monitoring valproic acid levels in epileptic children showed that higher plasma concentrations correlated with treatment resistance. A therapeutic range of 40-90 micrograms/ml is suggested for optimal seizure control.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology

Background:

  • Epilepsy management in children requires effective antiepileptic drugs.
  • Valproic acid is a widely used antiepileptic medication.
  • Understanding optimal therapeutic ranges is crucial for patient outcomes.

Purpose of the Study:

  • To monitor plasma valproic acid levels in epileptic children.
  • To correlate plasma concentrations with seizure control and treatment resistance.
  • To evaluate the efficacy of sodium valproate in different epilepsy types and combinations.

Main Methods:

  • Prospective monitoring of plasma valproic acid levels over two years in 90 epileptic children.
  • Analysis of seizure control in patients on monotherapy and combination therapy.
  • Statistical comparison of plasma levels between controlled and uncontrolled patient groups.

Main Results:

  • 82% of children on sodium valproate monotherapy achieved seizure control at a mean plasma level of 65.1 +/- 20.3 micrograms/ml.
  • Higher plasma levels (91.7 +/- 35.2 micrograms/ml) were associated with treatment resistance (p = 0.008).
  • Side effects, including appetite increase and gastrointestinal issues, were observed in 21% of patients, often with levels above 70 micrograms/ml.

Conclusions:

  • Sodium valproate appears effective for absences, tonic-clonic, and partial seizures.
  • A therapeutic plasma concentration range of 40-90 micrograms/ml is proposed for sodium valproate in children.
  • Treatment resistance may be linked to plasma levels outside the proposed therapeutic range.

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...